Risk factors in multiple myeloma: is it time for a revision?
Jill Corre, Nikhil C. Munshi, Hervé Avet‐Loiseau
Abstract
Although therapeutic strategies have been adapted to age and comorbidities for a long time, almost all multiple myeloma (MM) patients currently receive similar treatment, whatever their disease risk category. However, high-risk MM patients still constitute an unmet medical need and should benefit from the most efficient drug combinations. Herein, we review and discuss how to optimally define risk and why a revision of the current definition is urgently needed.
Topics & Concepts
Multiple myelomaMedicineIntensive care medicinePomalidomideLenalidomideInternal medicineMultiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsCancer therapeutics and mechanisms